ArticlePloS one2025
New potentials in biomedical application of hydrated electrons: A functional and biomedical effects study of an electromagnetic base liquid containing hydrated electrons.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrated electrons (eaq-) are widely studied in pollutant degradation owing to their high reducing power. Recent studies indicate that transiently generated eaq- during radiotherapy can enhance chemotherapeutic antitumor effects via reduction activity. However, biomedical applications remain limited because conventional methods generate eaq- in situ and are short-lived, precluding storage. In this study, we present a storable electromagnetic base liquid (EBL), reference-linked to prior preparation work, and analyze its physicochemical and organism-level effects. The EBL showed strong alkalinity (pH 13.08), low oxidation-reduction potential (ORP 47.1 mV), and a total antioxidant capacity of 1.6 mM Trolox equivalents antioxidant capacity. Using a larva zebrafish (Danio rerio) digital phenotyping platform, we identified a non-adverse concentration and generated unbiased predictions clustering EBL with antitumor, uric acid-lowering, and hypoglycemic drugs. These findings motivate further biological investigation of EBL's biomedical potential and provide a basis for subsequent validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.